Thromboembolism

Also known as: Thrombus / Thromboembolic event / Thromboembolism NOS / Embolism and thrombosis of unspecified site / Embolism / Embolism NOS

DrugDrug NameDrug Description
DB00945Acetylsalicylic acidAlso known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer [A177325]. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others [L5968]. Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label].
DB01109HeparinUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
DB00682WarfarinWarfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
DrugDrug NameTargetType
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidNuclear factor kappa b beta subunittarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidTumor necrosis factor-inducible gene 6 proteintarget
DB00945Acetylsalicylic acidCaspase-1target
DB00945Acetylsalicylic acidCaspase-3target
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidExtracellular signal-regulated kinase (ERK)target
DB00945Acetylsalicylic acidG1/S-specific cyclin-D1target
DB00945Acetylsalicylic acidMyc proto-oncogene proteintarget
DB00945Acetylsalicylic acidProliferating cell nuclear antigentarget
DB00945Acetylsalicylic acidCyclin Atarget
DB00945Acetylsalicylic acidUDP-glucuronosyltransferase 1-6enzyme
DB00945Acetylsalicylic acidArylamine N-acetyltransferase 2enzyme
DB00945Acetylsalicylic acidSolute carrier family 22 member 8transporter
DB01109HeparinAntithrombin-IIItarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinP-selectintarget
DB01109HeparinHeparanaseenzyme
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01109HeparinThyroxine-binding globulincarrier
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 1A1enzyme
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DrugDrug NamePhaseStatusCount
DB06605Apixaban1Recruiting1
DB06228Rivaroxaban1 / 2Completed1
DB00945Acetylsalicylic acid2Completed1
DB03496Alvocidib2Completed1
DB12364Betrixaban2Completed1
DB00758Clopidogrel2Completed1
DB06695Dabigatran etexilate2Terminated1
DB06779Dalteparin2Completed1
DB12289Darexaban2Completed2
DB01248Docetaxel2Completed1
DB00997Doxorubicin2Completed1
DB09075Edoxaban2Completed2
DB01225Enoxaparin2Completed4
DB01196Estramustine2Completed1
DB00569Fondaparinux2Completed1
DB00441Gemcitabine2Completed1
DB01026Ketoconazole2Completed1
DB00125L-Arginine2Completed1
DB06228Rivaroxaban2Completed1
DB00682Warfarin2Completed2
DB00682Warfarin2Terminated1
DB06779Dalteparin2 / 3Completed1
DB06822Tinzaparin2 / 3Completed1
DB00945Acetylsalicylic acid3Completed1
DB09261Certoparin3Completed1
DB06695Dabigatran etexilate3Completed7
DB06695Dabigatran etexilate3Not Yet Recruiting1
DB06779Dalteparin3Terminated1
DB06779Dalteparin3Unknown Status1
DB09075Edoxaban3Completed1
DB01225Enoxaparin3Completed4
DB00569Fondaparinux3Completed2
DB11728Fondaparinux3Completed2
DB00569Fondaparinux3Terminated1
DB00441Gemcitabine3Terminated1
DB01109Heparin3Completed1
DB06228Rivaroxaban3Completed2
DB12823Tecarfarin3Not Yet Recruiting1
DB00682Warfarin3Completed7
DB00682Warfarin3Not Yet Recruiting1
DB04898Ximelagatran3Terminated1
DB00945Acetylsalicylic acid4Completed2
DB00009Alteplase4Completed1
DB00009Alteplase4Recruiting1
DB06605Apixaban4Recruiting1
DB06695Dabigatran etexilate4Withdrawn1
DB06779Dalteparin4Terminated1
DB01225Enoxaparin4Unknown Status1
DB01109Heparin4Completed1
DB01109Heparin4Unknown Status1
DB08813Nadroparin4Completed1
DB08813Nadroparin4Unknown Status1
DB06228Rivaroxaban4Withdrawn1
DB01098Rosuvastatin4Completed1
DB06822Tinzaparin4Completed2
DB00013Urokinase4Completed1
DB00682Warfarin4Completed2
DB00945Acetylsalicylic acidNot AvailableCompleted1
DB06605ApixabanNot AvailableNot Yet Recruiting1
DB01225EnoxaparinNot AvailableCompleted3
DB11728FondaparinuxNot AvailableCompleted1
DB01109HeparinNot AvailableCompleted1
DB09264IdarucizumabNot AvailableRecruiting1
DB06228RivaroxabanNot AvailableNo Longer Available1
DB00682WarfarinNot AvailableCompleted1